The novel nature of the coronavirus disease 2019 (COVID-19) pandemic presents many challenges to gynecologists working to optimize the care of their patients. No part of our practice has been more disrupted than the ability to offer timely procedures to our patients with gynecologic surgical indications. Despite efforts to limit elective surgery during the COVID-19 pandemic, urgent and emergent procedures must still be performed. For many of these urgent procedures, such as ruptured ectopic pregnancy, hemorrhagic ovarian cysts, or ovarian torsion, laparoscopy may offer the best surgical approach and outcomes for the patient. However, some have suggested that laparoscopic procedures should be avoided and laparotomy procedures be universally employed when a patient is COVID-19 positive or status is unknown owing to concerns about aerosolization of viral particles through the pneumoperitoneum. We strongly disagree with this premise. On the basis of the best available evidence, we concur with both the recent US joint professional society statement on minimally invasive gynecology during the COVID-19 pandemic [@bib0001] and the European joint society statements, [@bib0002] endorsing laparoscopy as a safe surgical approach in this setting.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, is a respiratory pathogen. Both the RNA and the infectious virus are detected primarily from human upper and lower respiratory tract specimens. The COVID-19 virions are approximately 0.125 μm in size and are most commonly transmitted as larger (\>20 μm) respiratory water droplets. The virus may also be aerosolized and transmitted in smaller droplets (\<10 μm) in gas suspension. Particle size has implications for suspension time and filtration requirements. SARS-CoV-2 RNA has also been detected in blood and stool specimens, but it is unknown if infectious virus is present in these extrapulmonary specimens [@bib0003]. To date, no studies have identified SARS-CoV-2 in surgical smoke, and even if found, it is not known whether these viral particles are infectious. In addition, whereas viral RNA may be detected in the blood, no transmission of COVID-19 has been documented through this route [@bib0004].

What have we learned from other viral epidemics and surgical risks? That the risk of viral disease transmission with laparoscopy is virtually zero. Although the viral DNA of blood-borne viral pathogens, such as hepatitis B and HIV, have been detected in surgical plume after the use of surgical energy (e.g., electrosurgery, laser and harmonic scalpel), there is no evidence to indicate that the use of electrosurgery during laparoscopy increases the risk of disease transmission through the surgical plume or pneumoperitoneum \[[@bib0005],[@bib0006]\]. Furthermore, surgery in patients with HIV and hepatitis B and C has been ongoing for decades, without documented increased risk of transmission from the surgical plume or laparoscopic pneumoperitoneum to surgeons, anesthesiologists, or operating room (OR) personnel. When possible, laparoscopic techniques that significantly minimize exposure of surgeons to blood-borne pathogens are far preferred to laparotomy.

In addition, although COVID-19 is a novel disease, evidence from similar respiratory viruses, such as influenza and other coronaviruses (severe acute respiratory syndrome \[SARS\] and Middle East respiratory syndrome \[MERS-CoV\]), have not shown disease transmission through surgical plume or laparoscopic gas during previous viral epidemics or annual influenza seasons [@bib0007]. The bottom line is there are no compelling data to support the notion that respiratory or blood-borne infectious viruses are transmitted through the surgical plume or aerosolized laparoscopic gas.

One must also consider the adverse impact of adopting overarching policy changes (such as "laparotomy is better during the COVID-19 pandemic because of theoretic aerosolization risks") on the basis of erroneous assumptions. What is not theoretic is that converting more cases to laparotomy during the COVID-19 pandemic will have dire downstream consequences, including prolonged hospital stays and bed use, an increased likelihood of intensive care unit stay, greater risk of patient harm from surgical complications (including undesirable pulmonary issues during a respiratory viral crisis), and greater risks of COVID-19 exposure for both the patient and healthcare providers. Given the lack of data to support the claim that COVID-19 virus spreads through the laparoscopic smoke plume or pneumoperitoneum, one cannot justify the increased use of precious resources, greater number of surgical complications, and infectious exposure risks to the patient and the caregivers that would result if laparoscopic approaches were abandoned during this period.

Nevertheless, despite this reassuring data, precautions should be considered to minimize any potential or theoretic risks during the COVID-19 pandemic. There are several relevant safety considerations for clinical teams who participate in gynecologic surgery during this time. Laparoscopy most commonly involves general anesthesia, with the associated intubation, extubation, and mechanical ventilation, which may produce airborne viral droplets in a patient who is COVID-19 positive. General anesthesia is not contraindicated in patients who are confirmed as COVID-19 positive, but the surgical team should minimize exposure to airborne virus during intubation and extubation and OR personnel should don adequate personal protective equipment (PPE), including face shields, N95 filtered masks if available, gowns, and gloves. Even if it is assumed that limited viral particles may become airborne through the pneumoperitoneum during laparoscopy, the OR is one of the safest places in the hospital to avoid COVID-19 exposure because of the air filtration/circulation in most standard ORs, the sterile field, and the fact that surgeons and anesthesiologist will be wearing PPE. Several techniques can be used to minimize the potential risk of airborne viral particles at the time of surgery via any route and specifically during laparoscopy. Performing laparoscopy with lower intra-abdominal carbon dioxide pressures and minimizing the use of energy will limit the production of surgical plume and pneumoperitoneum. In addition, the use of a smoke evacuation/filtration system allows for controlled release and filtration of the surgical plume. Ideally, gas and plume evacuation and filtration are accomplished with the use of an ultralow particulate air filter rated to screen particles of 0.1 μm in diameter (e.g., the ConMed Airseal; ConMed, Utica, NY or Stryker Pneumoclear; Stryker, Kalamazoo, MI). In contrast, high efficiency particulate air filters are only required to filter particles of 0.3 μm in diameter. N95 masks are rated to filter out at least 95% of very small (0.3 μm) particles [@bib0003]. Whereas smoke evacuation and filtration systems can be used both at the time of laparoscopy and laparotomy, laparoscopy offers the unique advantage of being able to almost entirely contain the surgical plume in the abdominal cavity. In conjunction with tightly fitting laparoscopic ports, an evacuation/filtration system can be used to minimize the release of potential airborne virus into the OR environment, while simultaneously evacuating the surgical smoke actively or passively. It is important to avoid a sudden release of the pneumoperitoneum. This is most relevant before tissue extraction, whether via a minilaparotomy or vaginally, and at the completion of the surgery. At these times, the abdominal cavity should be actively desufflated through a filtration system or with a simple piece of tubing attached to a suction canister, rather than releasing the pneumoperitoneum into the OR. The use of a containment bag for tissue extraction can help maintain the seal and may limit the loss of pneumoperitoneum.

This is in contrast to smoke evacuation at the time of laparotomy, when containment of the surgical smoke is challenging, if not impossible. The smoke evacuator must ideally be within 2 cm of the source, with 50% loss of capture for every 1 cm from the source of the plume. If COVID-19 particles can indeed be disseminated into the surgical plume, then surgeons and OR personnel may be more likely to experience direct exposure to viral particles from a laparotomy approach.

In summary, laparoscopy remains the preferred surgical approach for gynecologic patients during the COVID-19 pandemic for most surgical indications. The theoretic risk of airborne SARS-CoV-2 from an abdominal source at the time of surgery has not been substantiated. There is no current evidence that infection of OR personnel occurs by means of laparoscopy any more so than by laparotomy surgery. However, given the paucity of data, it is prudent to take precautions in the OR given that viral particles can be aerosolized during intubation and extubation. We believe laparoscopy offers the opportunity for better containment and filtration of the surgical gas and plume compared with laparotomy and continues to offer vastly more health benefits, particularly during the COVID-19 pandemic and when precious PPE and hospital resources and minimization of viral exposure risks are so critical to mitigating this public health crisis. Let us not lose sight of the "scope" of the problem: it is imprudent and even dangerous to blindly abandon tried-and-true, safe surgical practices during a viral pandemic. Laparoscopy, when clinically appropriate, achieves the goal of optimizing patient care and outcomes, while minimizing risk to the surgical and perioperative teams.
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